CОMBINED TREATMENT OF PATIENTS WITH GRADE 2 OBESITY

Authors

  • L. V. Naumova I. Horbachevsky Ternopil National Medical University
  • L. S. Milevska-Vovchuk I. Horbachevsky Ternopil National Medical University
  • Y. V. Boiko I. Horbachevsky Ternopil National Medical University
  • U. O. Naumova I. Horbachevsky Ternopil National Medical University
  • S. O. Gruba I. Horbachevsky Ternopil National Medical University

DOI:

https://doi.org/10.11603/bmbr.2706-6290.2020.4.11433

Keywords:

metformin, GLP-1 analogs, obesity

Abstract

Summary. Obesity is a rapidly spreading modern pandemic that requires continuous improvement of treatment regimens while maintaining an individual approach to each patient.

The aim of the study – to analyze the effectiveness of drug correction in patients with grade 2 obesity by comparing two groups of sugar-lowering drugs biguanides and glucagon-like peptide-1 analogues.

Materials and Methods. Comparison of effectiveness of two groups of hypoglycemic drugs in patients with grade 2 obesity in order to discover their impact on body weight dynamics.

Results. The paper presents the results of a comparative analysis of the use of biguanids and analogues of GLP-1 in patients with grade II obesity.

Conclusions. The authors note a more pronounced effect of the use of analogues of GLP-1 in patients with grade II obesity compared with drugs of the metformin group. However, both groups of drugs showed a statistically significant decrease in body weight in the study groups.

References

Flegal KM. Prevalence and trend in obesity among US adults 2000-2010. JAMA. 2012;288: 1723-7.

Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol. Clin North Am. 2010;39(1): 1-7.

Wang Y, Beydoun M. The obesity epidemic in the United States – gender, age, 480 socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and 481 meta-regression analysis. Epidemiol Rev. 2007;29: 6-28.

Ogden CL, Lamb MM, Carroll MD, Flegal KM. Obesity and socioeconomic status in adults: United States, 2005-2008. NCHS Data Brief. 2010;50: 1-8.

Antonyshyn IV, Marushchak MI, Denefil OV. [The state of lipid peroxidation in experimental diet-induced alimentary obesity]. Medychna khimiia. 2014;16(3): 61-5. Ukrainian.

Marushchak MI, Myalyuk OP, Gevko UP, Gabor GG, Yaroshenko TYa, Antonyshyn IV. [Analysis of the potential of the glutathione system in rats with alimentary obesity]. Medych ta klinich khimiia. 2017;2(71): 60-5. Ukrainian.

Bugrova SA. Obesity. Metabolic syndrome. Diabetes mellitus type 2. [Ожирение (этиология, патогенез, классификация). // Ожирение. Метаболический синдром. Сахарный диабет 2 типа]. Dedov Ed. Moscow: Meditsina. 2010. Russian.

James WPT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil. 2014;11: 3-8.

World Health Organization. Controlling the Global Obesity Epidemic. Geneva: World Health Organization. 2019; 21-38.

Miles JM, Leiter L, Hollander P, Anderson JW, Doyle M. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25: 1123-8.

Bilovol OM, Kovaleva OM, Popova SS, Tveretinov OB. Obesity in the practice of cardiologist and endocrinologist. [Ожиріння в практиці кардіолога та ендокринолога] Ternopil: TDMU, “Ukrmedknyha”; 2009. Ukrainian.

Published

2021-02-25

How to Cite

Naumova, L. V., Milevska-Vovchuk, L. S., Boiko, Y. V., Naumova, U. O., & Gruba, S. O. (2021). CОMBINED TREATMENT OF PATIENTS WITH GRADE 2 OBESITY. Bulletin of Medical and Biological Research, (4), 49–52. https://doi.org/10.11603/bmbr.2706-6290.2020.4.11433